Oxford Genetics Announces Licensing Deal of its Lentivirus Plasmids
Oxford Genetics, a leading innovator of biopharmaceutical technologies, has signed a licensing agreement with world-class service organisation, Aldevron to bring to market a standardized range of its plasmids for lentiviral manufacture.
Ryan Cawood, CEO of Oxford Genetics commented, “This latest partnership showcases Oxford Genetics’ ability to develop and supply high quality technologies that can transform the gene therapy industry and outcompete commercial alternatives. We are really pleased to be working with such an industry leader as Aldevron and look forward to working with them to achieve broad market adoption of the technology.”
Oxford Genetics’ third-generation Lentiviral packaging plasmids have been optimized to give high-level production of Lentiviral vectors. The licensed Excelenti technology is composed of an optimized ratio of 4 plasmids which have been engineered to improve the production of lentiviral gene therapy vectors.
These four plasmids can be used for recombinant lentiviral vector production, thereby allowing gene therapy innovators to benefit from shared large-scale production and fast delivery times afforded by Aldevron.
“Genetic medicine has experienced tremendous growth with the approval of multiple products that dramatically improve life,” said Michael Chambers, Aldevron’s CEO. “Lentiviral vectors are the key component for manufacturing many of these treatments. The free availability of lentiviral packaging plasmids will significantly reduce the time and cost to develop and commercialize these products.”
“At Oxford Genetics we offer a range of technology solutions for the design, discovery and development of viral and protein therapies as well as Gene Editing, making us a versatile partner and supplier to the industry. We’ve seen our business go from strength to strength over the past 18 months and I’m very proud of the innovations the team here continues to deliver” said Ryan Cawood.
Speaking at Phacilitate Leaders World 2019, James Brown & Andrew Ward reveal the opportunities that the partnership’s means for its customers.
About Oxford Genetics
Oxford Genetics is a leading synthetic biology company focused on developing novel technologies to overcome the challenges associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines. Our proprietary genomic system enables the precise engineering of DNA, which in combination with our automated platforms, drive the rational design of complex biologics and their associated production processes, with the overarching aim of increasing predictability, robustness and scalability, while lowering cost and human error.
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-SourceTM quality system. Company headquarters are in Fargo, North Dakota, with additional facilities in Madison, Wisconsin, and Freiburg, Germany.